Key result
Early and continuous statin therapy during and after hospitalization reduced the 6-month risk of major adverse cardiac events compared to no statin therapy.
Why the study?
Does early and continuous statin therapy improve 6-month MACE in STEMI patients undergoing PCI compared to interrupted or no statin therapy?
Cohort (n=3,584)
Yes
Does early and continuous statin therapy improve 6-month MACE in STEMI patients undergoing PCI compared to interrupted or no statin therapy?
Early and continuous statin therapy during and after hospitalization significantly reduces 6-month major adverse cardiac events in STEMI patients undergoing PCI compared to delayed, interrupted, or no statin therapy.
Answers are grounded in this paper and cite their sources.
Should not yet change statin protocols in STEMI PCI; leaves open causal benefit pending randomized confirmation.
BACKGROUND: The benefit of statin use after acute ST-segment elevation myocardial infarction (STEMI) has been well established, however, the influence of the timing of statin administration has not been elucidated. The objective of this study focused on early clinical outcomes after percutaneous coronary intervention (PCI). METHODS: This analysis of the Korea Working Group on Myocardial Infarction registry (KorMI) study included 3,584 STEMI patients (mean age, 63 ± 13 years; male, 2,684, 74.9%) undergoing PCI from January 2008 to June 2009. Rates of major adverse cardiac events (MACE: all-cause death, recurrent MI, and target lesion revascularization) were compared among patients grouped according to statin therapy timing: I, both during and after hospitalization (n = 2,653, 74%); II, only during hospitalization (n = 309, 8.6%); III, only after discharge (n = 157, 4.4%); and IV, no statin therapy (n = 465, 13%). Mean follow-up duration was 234 ± 113 days. RESULTS: Multivariate factors of statin use during hospitalization included prior statin use, multiple diseased vessels, final thrombolysis in myocardial infarction flow grade III, and low-density lipoprotein cholesterol level. At 6-month follow-up, groups III and IV had the highest MACE rates (2.3%, 3.9%, 5.1%, and 4.9% for groups I-IV, respectively, P = 0.004). After adjusting for confounders, groups II-IV had a higher MACE risk than group I [hazard ratio (HR): 3.20, 95% confidence interval (95%CI): 1.31-7.86, P = 0.011; HR: 3.84, 95%CI: 1.47-10.02, P = 0.006; and HR: 3.17, 95%CI: 1.59-6.40, P = 0.001; respectively]. CONCLUSIONS: This study, based on the national registry database, shows early and continuous statin therapy improvs early outcomes of STEMI patients after PCI in real-world clinical practice.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2014) conducted a cohort in Acute ST-segment elevation myocardial infarction (STEMI) (n=3,584). Statin therapy both during hospitalization and after discharge vs. No statin therapy was evaluated on 6-month composite of major adverse cardiac events (MACE: all-cause death, recurrent MI, and target lesion revascularization) (HR 3.17, 95% CI 1.59-6.40, p=0.001). Early and continuous statin therapy during and after hospitalization reduced the 6-month risk of major adverse cardiac events compared to no statin therapy.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: